BICYCLIC HETEROCYCLIC INHIBITORS OF FGFR4, PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS CONTAINING THEM, AND USE THEREOF Russian patent published in 2024 - IPC C07D471/04 C07D491/20 A61K31/444 A61K31/4545 A61K31/519 A61K31/5377 A61P35/00 A61P35/02 

FIELD: medical chemistry.

SUBSTANCE: present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof. In formula (I): X is CH; Y is 1 O; Z is C(R⁶)₂; m is 0 or 1; L is -C (R⁷)₂- or n is 0, 1 or 2; each R¹ is independently C_1-3 alkyl or C_1-3 haloalkyl; R² and R³ each independently represents a halogen; R⁴ is hydrogen; R⁵ is hydrogen; two R⁶ and carbon atoms to which they are bonded together form C_3-8 cycloalkyl or 4–10-membered heterocycloalkyl; where 4–10-membered heterocycloalkyl includes 1 ring-forming heteroatom O; each R⁷ is independently hydrogen, halogen, C_1-8 alkyl, 3–10 membered heterocycloalkyl or 3–10 membered heterocycloalkyl, substituted with C_1-4 alkyl or morpholinyl; wherein said 3–10-membered heterocycloalkyl independently includes 1 to 2 ring-forming heteroatoms, and each of said heteroatoms is independently N, O. Also disclosed is a pharmaceutical composition and a pharmaceutical preparation containing said compound, and use thereof.

EFFECT: disclosed compound can be used as an FGFR4 inhibitor for preventing and/or treating diseases mediated, at least partially, by FGFR4.

11 cl, 2 tbl, 19 ex